NCT01617135View on ClinicalTrials.gov

"Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and Off Episodes"

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

December 31, 2012

Conditions
Idiopathic Parkinson's Disease
Interventions
DRUG

CVT-301

DRUG

Placebo

DRUG

Sinemet (carbidopa/levodopa)

DRUG

CVT-301

Trial Locations (7)

Unknown

Civitas Clinical Site #6, Petah Tikva

Civitas Clinical Site #5, Tel Aviv

Civitas Clinical Site #4, Belgrade

Civitas Clinical Site #7, Belgrade

Civitas Clinical Site #1, Glasgow

Civitas Clinical Site #3, Newcastle

Civitas Clinical Site #2, Norwich

Sponsors
All Listed Sponsors
collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

Acorda Therapeutics

INDUSTRY

NCT01617135 - "Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and Off Episodes" | Biotech Hunter | Biotech Hunter